Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03KZM
|
|||
| Former ID |
DAP001530
|
|||
| Drug Name |
Tolvaptan
|
|||
| Synonyms |
Samsca; OPC 41061; Benzazepine derivative, 32; OPC-41061; Samsca (TN); N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide; (-)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide; 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyponatraemia [ICD-11: 5C72; ICD-10: E87; ICD-9: 276.1] | Approved | [1], [2] | |
| Heart failure [ICD-11: BD10-BD13; ICD-10: I50, I50.9; ICD-9: 428] | Phase 3 | [1], [2] | ||
| Company |
Otsuka; Winston Laboratories & Otsuka
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H25ClN2O3
|
|||
| Canonical SMILES |
CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C
|
|||
| InChI |
1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
|
|||
| InChIKey |
GYHCTFXIZSNGJT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 150683-30-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9372812, 12015154, 14833208, 30419982, 47510146, 47657166, 51204548, 53789150, 57399753, 85210210, 85856516, 103375036, 103991970, 113461194, 124894207, 125341597, 126624049, 126646501, 126667032, 128023819, 134338710, 134340568, 135135410, 135651270, 135692541, 137249406, 138069831, 144206807, 152134154, 160827363, 162038188, 162172255, 163093186, 163391946, 163884836, 172085105, 172914598, 175424760, 179149970, 187072445, 196109765, 198993114, 204366097, 208265503, 211536279, 223383397, 223659992, 224337427, 226592757, 242060063
|
|||
| ChEBI ID |
CHEBI:32246
|
|||
| ADReCS Drug ID | BADD_D02246 | |||
| SuperDrug ATC ID |
C03XA01
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vasopressin V2 receptor (V2R) | Target Info | Antagonist | [2], [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Vasopressin-regulated water reabsorption | ||||
| Pathwhiz Pathway | Vasopressin Regulation of Water Homeostasis | |||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Reactome | Vasopressin-like receptors | |||
| G alpha (s) signalling events | ||||
| Vasopressin regulates renal water homeostasis via Aquaporins | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Regulation of Water Balance by Renal Aquaporins | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2226). | |||
| REF 2 | Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. | |||
| REF 3 | Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.